

# PRODUCT INFORMATION



**TD-165**

Item No. 44837

**CAS Registry No.:** 2305936-56-3  
**Formal Name:** (2S,4R)-1-((2S)-2-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)undecanamido)-3,3-dimethyl-butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

**MF:** C<sub>46</sub>H<sub>59</sub>N<sub>7</sub>O<sub>8</sub>S

**FW:** 870.1


**Purity:** ≥95%

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



## Laboratory Procedures

TD-165 is supplied as a solid. A stock solution may be made by dissolving the TD-165 in the solvent of choice, which should be purged with an inert gas. TD-165 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in ethanol.

## Description

TD-165 is a proteolysis-targeting chimera (PROTAC) that contains VH 032 (Item No. 39982) conjugated to the cereblon (CRBN) inhibitor pomalidomide (Item No. 19877).<sup>1</sup> It induces degradation of CRBN in HEK293T cells with a half-maximal degradation concentration (DC<sub>50</sub>) value of 20.4 nM. TD-165 (0.5 μM) increases L-type voltage-gated calcium channel 1.2α (Ca<sub>v</sub>1.2α) levels in AC16 ventricular cardiomyocytes.<sup>2</sup> It increases left ventricle pressure and heart rate in mice. Intra-articular administration of TD-165 (1.5 μg/joint) decreases disease severity and subchondral bone plate thickness in a mouse model of osteoarthritis induced by destabilization of the medial meniscus.<sup>3</sup>

## References

- Kim, K., Lee, D.H., Park, S., *et al.* Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. *Sci. Rep.* **9(1)**, (2019).
- Park, N., Marquez, J., Pham, T.K., *et al.* Cereblon contributes to cardiac dysfunction by degrading Ca<sub>v</sub>1.2α. *Eur. Heart J.* **43(20)**, 1973-1989 (2022).
- Lee, Y., Kim, H.-E., Kwak, J.-S., *et al.* The cereblon-AMPK (AMP-activated protein kinase) axis in chondrocytes regulates the pathogenesis of osteoarthritis. *Osteoarthritis Cartilage* **32(12)**, 1579-1590 (2024).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/29/2026

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM